Bioprocessing Is Becoming a Smarter Manufacturing System

Bioprocessing is becoming a more connected manufacturing discipline, as bioreactor control, bioseparation, automation, and AI increasingly operate as parts of the same production system. The opportunity is not simply to add new technology, but rather to improve how the entire process performs.

Image

Bioprocessing Is Moving Beyond Individual Unit Operations

Modern biomanufacturing depends on a chain of interdependent decisions.

Cell culture or fermentation affects the material entering downstream processing. Downstream recovery affects yield and purity. Process control influences both. Data from sensors and analytical systems can inform decisions throughout the process.

That makes bioprocessing a systems problem, rather than a collection of separate manufacturing steps.

For industrial biotechnology and bioseparation it’s important to highlight this shift. Advances in membrane separation, aqueous two-phase extraction, improved chromatographic materials, process integration, automation, and greener processing are all important routes towards more efficient production.

However, better upstream performance is valuable only if downstream operations can recover the product efficiently. Higher titres do not automatically translate into better manufacturing economics if purification becomes the bottleneck.

This is where the entire Chain Reaction, from start to finish, is most important.

Bioprocessing Starts with Process Control

Biological systems are difficult to control because they change significantly over time.

Cell growth, metabolism, oxygen demand, nutrient consumption, temperature, pH, and other process variables interact. A change in one can affect several others.

This a significant challenge, and classical control approaches still account for more than 90% of industrial bioprocess controls, while increasing process complexity, nonlinearity, and digitisation are creating a stronger case for advanced process control.

That does not mean traditional control suddenly becomes obsolete.

It does mean manufacturers need better layers of process understanding around existing control infrastructure.

Image

Advanced sensors, process analytical technology (PAT), soft sensors, mechanistic models, and model-based control can provide a richer picture of what is happening inside the bioreactor.

This matters because improved process visibility can support earlier intervention rather than relying on end-of-batch testing to reveal problems.

View interview How Should Pharma Companies Audit AI Vendors?

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."

Image

AI Turns Manufacturing Data Into Process Intelligence

AI and machine learning add another layer to this manufacturing architecture.

AI applications range from process monitoring and optimisation to fault detection, predictive maintenance, digital twins, and deviation investigations. 

The important point is not that every bioprocess needs a sophisticated AI model.

The value depends on the manufacturing question being solved.

For example, machine learning can analyse high-dimensional process data to identify patterns that are difficult to detect manually and models can support prediction of process performance, identify unusual behaviour, or help optimise operating conditions.

Digital twins offer another route. Models of cell culture processes can combine historical and real-time information to forecast process behaviour and test scenarios before changing the physical process. Such applications include cell-culture digital twins and predictive maintenance. 

But more complex models are not automatically better.

Advanced machine-learning approaches often require substantial datasets, while process scientists may still favour simpler models when they deliver comparable performance and greater interpretability. 

That is an important lesson for manufacturing teams: Model sophistication should follow process need, not technology fashion.

Downstream Processing Is a Strategic Lever

The manufacturing conversation often focuses heavily on upstream productivity.

But that risks missing a major source of value.

Bioseparation directly affects product purity, recovery, and manufacturing cost. Areas of development include membrane technologies, aqueous two-phase extraction, tailored chromatographic materials, biomimetic approaches, and process intensification.

This changes how Technical Operations should evaluate process improvement.

A higher-producing cell line is not necessarily the better manufacturing solution if its product creates a difficult purification problem. Likewise, a downstream process that achieves purity but requires excessive water, energy, processing time, or material consumption may not be optimal at commercial scale.

Upstream and downstream development therefore need to be treated as one economic system.

Image

That principle also strengthens the case for continuous monitoring and integrated process control.

If data can move between unit operations, manufacturers gain a better view of where losses occur and where intervention can produce the greatest effect.

The Next Step Is Connected, Not Simply Automated

Automation is already established across biomanufacturing. The more significant shift is towards connected automation.

Industrial automation, advanced process control, digitisation, process analytical technology, and single-use technology are all important components of modern biopharmaceutical processing. 

This can go further with AI operating across manufacturing activities while maintaining the need for appropriate validation, data governance, security, traceability, and model lifecycle management.

That creates a whole new responsibility for manufacturing teams.

A connected manufacturing environment must connect more than equipment. It must connect process data, quality decisions, engineering knowledge, validation, and regulatory controls.

This is why bioprocessing digitalisation cannot sit entirely within IT.

Manufacturing scientists, process engineers, automation specialists, Quality, CMC, and regulatory teams all have a role in determining how data-driven systems should operate.

Bioprocessing Needs a Stronger Chain Reaction

The next generation of biopharmaceutical manufacturing will not be defined by a single technology, but instead will depend on how well manufacturers connect bioreactor control, process analytical technology, downstream processing, automation, data, and advanced analytics.

Even from different starting points, the evidence shows that industrial biotechnology needs more efficient and sustainable separation.

Bioreactor systems need more sophisticated control as processes become increasingly complex. AI and machine learning can provide additional capabilities, but only when supported by suitable data, process understanding, and governance.

Being able to successfully integrate the technologies into one system turns digital bioprocessing into an operational capability.

At Pharmatica, we examine the systems, strategies, and technologies shaping pharmaceutical Technical Operations. Our Insights connect manufacturing innovation, process science, data, and operational resilience to the decisions that determine whether new technologies deliver measurable value.

Pharmatica: Insight. Connection. Impact.

Image